Drug crarisee obesity will be important

Copenhagen, Denmark – Novo Nordisk The disappointing results defended from the trials for its publicized Cagerio Candidate for the next -generation obesity drug, insisting that it will be a “important” weight loss treatment.

The CEO Lars Fruerd Jørgensen recognized on Thursday the acute reaction of the price of the shares after two consecutive trials in the late stage showed a disappointing weight reduction compared to the company’s objectives, but said that, however, it remained “encouraged” by the drug weight loss profile.

“I am very sure of Cagrisema,” he told the shareholders of the annual general meeting of the firm in Copenhagen, Denmark.

“It will be an important product for us.”

Cagrisema is a combination of Cagrilintide, a nascent form of weight loss treatment known as amiline analogue, and semaglutida, the active ingredient in Wagovy.

The main results of a redefinir-2 test in late stage released Earlier this month, he showed that cagrisee helped obese or overweight adult patients with type 2 diabetes to lose 15.7% of their weight for 68 weeks, compared to 3.1% with placebo. This was below the percentage of previously previously predicted weights.

A previous test in the late stage published In December, the medicine helped obese or overweight patients with one or more comorbidities, but not type 2 diabetes, to reduce their weight by 22.7% after 68 weeks, also below the 25% expected.

Both results eliminated a significant value of the price of Novo’s shares such as the hope of investors to find an alternative greater than the company’s injection and rival of the company. Eli Lily’s Zepbound, both GLP-1 medications, were faded. The time Darling Stock has now dropped more than 50% since its maximum 2024.

The Danish pharmaceutical giant faced a setback once again on Thursday, since the shareholders urged the Board of clearer and tactically solid judgments and objectives in an attempt to cause price movements of less dramatic actions.

Fruerd Jørgensen acknowledged criticism, particularly around the failure of the company to accurately communicate the flexible test design, which raised questions about tolerability, with less than two thirds of patients who progress at the highest dose after 68 weeks.

“22.7% is not 25%, so some people were disappointed by that,” he said, however, he added that the company believes that there is “continuous potential to develop a cagisema even more”, even when extending the trial period and the general dose.

Novo Nordisk is now carrying out a new phase 3 test, called Redefine 11, which “will further explore the potential of Cagrisema,” said the CEO.

It occurs when the weight loss industry remains divided on the broader applications and results of obesity medications beyond the total weight reduction. In a note earlier this month, Bofa Global Research said that it had grown “a little more cautious in differentiation” in the treatment of obesity and diabetes after the last results of Cagrisema.

However, Soren Lontoft, pharmaceutical capital analyst at Sydbank, said CNBC last week that a wide range of treatments was necessary to address both obesity and tolerability levels, as well as associated health risks such as cardiovascular disease, sleep apnea and liver disease.

“It is clear that there is a very large market opportunity, but it also requires a portfolio of products that meet the different needs of patients,” said Fruerd Jørgensen.